Verfügbarkeit: Myasthenia gravis | Technische Universität München

Myasthenia gravis:

Gespeichert in:

Bibliographische Detailangaben
Beteiligte Personen:	Köhler, Wolfgang 1957- (VerfasserIn), Sieb, Jörn Peter 1961- (VerfasserIn)
Format:	Buch
Sprache:	Deutsch
Veröffentlicht:	Bremen ; London ; Boston UNI-MED 2022
Ausgabe:	5. Auflage
Schriftenreihe:	UNI-MED Science
Schlagwörter:	Myasthenia gravis autoimmunologische Erkrankung Therapie
Links:	http://deposit.dnb.de/cgi-bin/dokserv?id=8fbbc38b8b6241d795d2c98065d12981&prov=M&dok_var=1&dok_ext=htm http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033847952&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
Umfang:	192 Seiten Illustrationen 24.6 cm x 17.6 cm, 496 g
ISBN:	9783837416312 3837416313

Internformat

MARC


LEADER	00000nam a2200000 c 4500
001	BV048470141
003	DE-604
005	20221221
007	t\|
008	220915s2022 gw a\|\|\| \|\|\|\| 00\|\|\| ger d
015			\|a 22,N37 \|2 dnb
016	7		\|a 1267777966 \|2 DE-101
020			\|a 9783837416312 \|c : EUR 44.80 (DE), EUR 46.10 (AT), CHF 74.00 (freier Preis) \|9 978-3-8374-1631-2
020			\|a 3837416313 \|9 3-8374-1631-3
024	3		\|a 9783837416312
035			\|a (OCoLC)1344383661
035			\|a (DE-599)DNB1267777966
040			\|a DE-604 \|b ger \|e rda
041	0		\|a ger
044			\|a gw \|c XA-DE-HB
049			\|a DE-384 \|a DE-578 \|a DE-19
084			\|a YG 6200 \|0 (DE-625)153508:12905 \|2 rvk
084			\|a YG 6203 \|0 (DE-625)153508:12909 \|2 rvk
084			\|a WE 555 \|2 nlm
084			\|8 1\p \|a 610 \|2 23sdnb
100	1		\|a Köhler, Wolfgang \|d 1957- \|e Verfasser \|0 (DE-588)137076835 \|4 aut
245	1	0	\|a Myasthenia gravis \|c Wolfgang Köhler, Jörn Peter Sieb
250			\|a 5. Auflage
264		1	\|a Bremen ; London ; Boston \|b UNI-MED \|c 2022
300			\|a 192 Seiten \|b Illustrationen \|c 24.6 cm x 17.6 cm, 496 g
336			\|b txt \|2 rdacontent
337			\|b n \|2 rdamedia
338			\|b nc \|2 rdacarrier
490	0		\|a UNI-MED Science
650	0	7	\|a Myasthenia gravis \|0 (DE-588)4075144-2 \|2 gnd \|9 rswk-swf
653			\|a Myasthenia gravis
653			\|a autoimmunologische Erkrankung
653			\|a Therapie
689	0	0	\|a Myasthenia gravis \|0 (DE-588)4075144-2 \|D s
689	0		\|5 DE-604
700	1		\|a Sieb, Jörn Peter \|d 1961- \|e Verfasser \|0 (DE-588)112255612 \|4 aut
710	2		\|a UNI-MED Verlag AG \|0 (DE-588)1065561733 \|4 pbl
780	0	0	\|i Vorangegangen ist \|z 9783837413083
856	4	2	\|m X:MVB \|q text/html \|u http://deposit.dnb.de/cgi-bin/dokserv?id=8fbbc38b8b6241d795d2c98065d12981&prov=M&dok_var=1&dok_ext=htm \|3 Inhaltstext
856	4	2	\|m DNB Datenaustausch \|q application/pdf \|u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033847952&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA \|3 Inhaltsverzeichnis
883	1		\|8 1\p \|a vlb \|d 20220910 \|q DE-101 \|u https://d-nb.info/provenance/plan#vlb
943	1		\|a oai:aleph.bib-bvb.de:BVB01-033847952

Datensatz im Suchindex

_version_	1819264562013143040
adam_text	6 INHALTSVERZEICHNIS INHALTSVERZEICHNIS YY EINLEITUNG 9 YY GESCHICHTE DER MYASTHENIA GRAVIS 10 YY KLINIK 17 3.1. KLINISCHE MANIFESTATIONSTYPEN ............................................................................................................... 17 3.1.1. OKULAERE MYASTHENIE ................................................................................................................................... 18 3.1.2. GENERALISIERTE MYASTHENIE ........................................................................................................................ 20 3.1.3. MYASTHENIE IM KINDESALTER (EOMG - EARLY ONSET MYASTHENIA GRAVIS) .................................................... 25 3.1.4. ALTERSMYASTHENIE (LOMG - LATE ONSET MYASTHENIA GRAVIS) .................................................................... 26 3.1.5. DIFFERENZIERUNG VERSCHIEDENER MYASTHENIE-VERLAUFSFORMEN NACH DEM ANTIKOERPER-STATUS ................ 27 3.2. VERLAUF ....................................................................................................................................................... 30 3.3. MYASTHENIE UND SCHWANGERSCHAFT ........................................................................................................ 32 3.3.1. EINFLUSS DER SCHWANGERSCHAFT AUF DIE MYASTHENIE .................................................................................. 32 3.3.2. EFFEKTE DER MYASTHENIE AUF DAS UNGEBORENE KIND, SCHWANGERSCHAFT UND GEBURTSVERLAUF ................ 33 3.3.3. MYASTHENIE-THERAPIE IN DER SCHWANGERSCHAFT UND STILLPHASE .............................................................34 3.3.4. NEONATALE MYASTHENIE ............................................................................................................................... 35 3.4. BEGLEITERKRANKUNGEN ............................................................................................................................... 37 3.5. EPIDEMIOLOGIE .......................................................................................................................................... 38 YY PATHOGENESE 40 4.1. NEUROMUSKULAERE SIGNALUEBERTRAGUNG ................................................................................................... 40 4.2. IMMUNMECHANISMEN ............................................................................................................................. 43 4.2.1. ANTI-ACHR-MYASTHENIE .............................................................................................................................43 4.2.1.1. HUMORALE MECHANISMEN .............................................................................................................................. 43 4.2.1.2. ZELLULAERE MECHANISMEN UND BEDEUTUNG DES THYMUS ................................................................................ 44 4.2.2. ANTI-MUSK-MYASTHENIE ............................................................................................................................. 46 YY DIAGNOSTIK 48 5.1. KOERPERLICHE UNTERSUCHUNG .................................................................................................................... 48 5.2. KLINISCHE KLASSIFIKATIONEN UND SCORES .................................................................................................. 50 5.2.1. KLASSIFIKATIONEN ......................................................................................................................................... 50 5.2.2. SCORES ZUR VERLAUFSBEURTEILUNG ................................................................................................................. 51 5.3. PHARMAKOLOGISCHE TESTUNG .................................................................................................................. 52 5.4. ELEKTROPHYSIOLOGIE ................................................................................................................................... 54 5.4.1. SERIENREIZUNG .............................................................................................................................................54 5.4.2. EINZELFASER-ELEKTROMYOGRAFIE ................................................................................................................... 58 5.4.3. STANDARD-ELEKTROMYOGRAFIE ...................................................................................................................... 59 5.4.4. STAPEDIUS-REFLEX ....................................................................................................................................... 59 5.5. ANTIKOERPERDIAGNOSTIK ............................................................................................................................. 60 5.5.1. ANTIKOERPER GEGEN DEN ACETYLCHOLINREZEPTOR ........................................................................................... 60 5.5.2. ANTIKOERPER GEGEN MUSK (MUSKELSPEZIFISCHE TYROSINKINASE) ................................................................. 62 5.5.3. LRP4-ANTIKOERPER UND ANDERE ANTIKOERPER BEI MYASTHENIE ...................................................................... 63 5.6. BILDGEBENDEVERFAHREN .......................................................................................................................... 64 5.7. WERTIGKEIT DIAGNOSTISCHER VERFAHREN .................................................................................................... 66 INHALTSVERZEICHNIS 7 B DIFFERENZIALDIAGNOSE 69 6.1. LEITSYMPTOM PTOSIS/DOPPELBILDER ....................................................................................................... 69 6.2. LEITSYMPTOM SCHWAECHE ......................................................................................................................... 73 6.2.1. BULBAERE SCHWAECHE ..................................................................................................................................... 73 6.2.2. SCHWAECHE DES KOPFHALTEAPPARATES ..........................................................................................................74 6.2.3. SCHWAECHE DER RUMPF UND EXTREMITAETENMUSKULATUR ............................................................................ 74 6.3. FUNKTIONELLE STOERUNGEN ......................................................................................................................... 75 6.4. ENDPLATTENERKRANKUNGEN .................................................. 75 6.5. LAMBERT-EATON MYASTHENISCHES SYNDROM (LEMS) ........................................................................... 75 6.5.1. PATHOGENESE .............................................................................................................................................. 76 6.5.2. EPIDEMIOLOGIE UND KLINISCHES BILD ........................................................................................................... 77 6.5.3. DIAGNOSTIK .................................................................................................................................................. 79 6.5.4. KOINZIDENZ MIT DER MYASTHENIE ............................................................................................................... 81 6.5.5. THERAPIE ..................................................................................................................................................... 81 6.6. BOTULISMUS ............................................................................................................................................... 83 6.7. NEUROMYOTONIE ........................................................................................................................................ 83 6.8. KONGENITALE MYASTHENIE-SYNDROME ................................................................................................... 84 6.8.1. KLINISCHES BILD ............................................................................................................................................86 6.8.2. KLINISCHE ZUSATZUNTERSUCHUNGEN ........................................................................................................... 86 6.8.3. FAMILIENANAMNESE UND MOLEKULARGENETIK .............................................................................................. 87 6.8.4. THERAPIE ..................................................................................................................................................... 88 YY THERAPIE 90 7.1. ALLGEMEINE THERAPIERICHTLINIEN ............................................................................................................ 90 7.2. ACETYLCHOLINESTERASE-INHIBITOREN ........................................................................................................ 91 7.2.1. PHARMAKOKINETIK ....................................................................................................................................... 92 7.2.2. DOSIERUNG UND NEBENWIRKUNGEN ........................................................................................................... 93 7.2.3. MYASTHENE VERSUS CHOLINERGE KRISE ......................................................................................................... 96 7.3. IMMUNOLOGISCH WIRKSAME THERAPIEFORMEN ...................................................................................... 96 7.3.1. GLUKOKORTIKOIDE ......................................................................................................................................... 96 7.3.1.1. THERAPIEEMPFEHLUNGEN ............................................................................................................................. 97 7.3.1.2. DOSIERUNG .................................................................................................................................................... 97 7.3.2. AZATHIOPRIN ................................................ 98 7.3.2.1 . WIRKMECHANISMEN UND PHARMAKOKINETIK ................................................................................................... 98 THERAPIESTUDIEN ......................................................................................................................................... 99 7.3.2.3. THERAPIEEMPFEHLUNGEN ............................................................................................................................ 100 7.3.3. MYCOPHENOLAT MOFETIL ............................................................................................................................. 101 7.3.3. 1. WIRKMECHANISMEN UND PHARMAKOKINETIK ................................................................................................ 101 7.33.2. THERAPIESTUDIEN ......................................................................................................................................... 102 7.3.4. TACROLIMUS ............................................................................................................................................... 103 7.3.5. CICLOSPORIN A ............................................................................................................................................ 103 73.5.1. WIRKMECHANISMEN UND PHARMAKOKINETIK ................................................................................................ 103 73.5.2. THERAPIESTUDIEN ......................................................................................................................................... 104 7.3.6. CYCLOPHOSPHAMID ................................................................................................................................... 104 7.3.7. METHOTREXAT ............................................................................................................................................ 105 7.3.8. RITUXIMAB ................................................................................................................................................. 105 73.8.1. WIRKMECHANISMUS .................................................................................................................................... 105 73.8.2. THERAPIESTUDIEN, ANWENDUNG UND RISIKEN .............................................................................................. 106 8 INHALTSVERZEICHNIS 7.3.9. ECULIZUMAB ............................................. 106 7.3.9.1. WIRKMECHANISMUS ..................................................................................................................................... 107 7.3.9.2. STUDIENDATEN ............................................................................................................................................. 107 7.3.9.3. THERAPIEDURCHFUEHRUNG .............................................................................................................................. 108 7.3.10. IMMUNGLOBULINE ...................................................................................................................................... 111 7.3.10.1. NEBENWIRKUNGEN ....................................................................................................................................... 113 7.3.10.2. DOSIERUNG .................................................................................................................................................. 113 7.3.11. INNOVATIVE THERAPIEOPTIONEN ................................................................................................................. 116 7.4. THERAPIE DER OKULAEREN MYASTHENIE .................................................................................................... 118 7.5. MYASTHENE KRISE .....................................................................................................................................118 7.5.1. ALLGEMEINES INTENSIV-MEDIZINISCHES MANAGEMENT ............................................................................. 120 7.5.2. SPEZIELLE THERAPIE DER MYASTHENEN KRISE .............................................................................................. 121 7.5.3. PLASMAPHERESE/IMMUNADSORPTION ......................................................................................................... 122 7.5.3.1. PLASMAPHERESE ............................................................................................................................................ 124 7.53.2. IMMUNADSORPTION ....................................................................................................................................... 126 7.53.3. VERGLEICH DER PLASMAPHERESE MIT DER IMMUNADSORPTION ......................................................................... 127 7.6. THYMEKTOMIE ........................................................................................................................................ 129 7.6.1. INDIKATION ................................................................................................................................................... 130 7.6.2. CHIRURGISCHES VORGEHEN .......................................................................................................................... 131 7.6.2.1 . TRANSSTERNALE THYMEKTOMIE ...................................................................................................................... 131 7.6.2.2. THORAKOSKOPISCHE THYMEKTOMIE .............................................................................................................. 132 7.6.23. ANAESTHESIE UND PERIOPERATIVE BETREUUNG ................................................................................................. 135 7.6.2.4. PROGNOSE UND VERLAUF ................................................................................................................................ 136 7.7. MYASTHENIE-INDUKTION UND -VERSCHLECHTERUNG DURCH MEDIKAMENTE .......................................137 7.7.1. IMMUNOLOGISCHE MYASTHENIE-INDUKTION ............................................................................................... 138 7.7.1.1. IMMUN-CHECKPOINT-INHIBITOREN (ICI) ......................................................................................................... 138 7.7.1.2. D-PENICILLAMIN UND CHLOROQUIN ................................................................................................................. 139 7.7.13. STATINE ......................................................................................................................................................... 139 7.7.1.4. WEITERE MEDIKAMENTE ................................................................................................................................ 140 7.7.2. MEDIKAMENTOESE MYASTHENIE-VERSTAERKUNG ............................................................................................. 140 7.7.2.1. ANTIBIOTIKA .................................................................................................................................................. 140 7.7.2.2. ANTIHYPERTENSIVA UND ANTIARRHYTHMIKA ...................................................................................................... 140 U.7.3. CHININ UND MAGNESIUM ............................................................................................................................... 141 U2A. WEITERE MEDIKAMENTE, HORMONE UND ROENTGENKONTRASTMITTEL .................................................................. 141 7.8. IMPFUNGEN ..............................................................................................................................................142 7.9. PHYSIKALISCHE THERAPIE .......................................................................................................................... 143 7.10. INTERMITTIERENDE HAEUSLICHE BEATMUNGSTHERAPIE BEI MYASTHENIA GRAVIS ...................................... 145 7.11. SOZIALE UND PSYCHOLOGISCHE ASPEKTE .................................................................................................147 7.12. SOZIALMEDIZINISCHE ASPEKTE ................................................................................................................. 148 7.12.1. EINSCHAETZUNG DES BEHINDERUNGSGRADS .................................................................................................. 148 7.12.2. MYASTHENIE UND FUEHRERSCHEIN ................................................................................................................ 149 YY ANHANG 150 8.1. ADRESSEN VON SELBSTHILFEORGANISATIONEN ........................................................................................... 150 8.2. LISTE MYASTHENIE-INDUKTION UND -VERSCHLECHTERUNG DURCH MEDIKAMENTE ................................ 150 8.3. KLINISCHE SCORES .................................. 152 YY LITERATUR 164 YY INDEX 189
any_adam_object	1
author	Köhler, Wolfgang 1957- Sieb, Jörn Peter 1961-
author_GND	(DE-588)137076835 (DE-588)112255612
author_facet	Köhler, Wolfgang 1957- Sieb, Jörn Peter 1961-
author_role	aut aut
author_sort	Köhler, Wolfgang 1957-
author_variant	w k wk j p s jp jps
building	Verbundindex
bvnumber	BV048470141
classification_rvk	YG 6200 YG 6203
ctrlnum	(OCoLC)1344383661 (DE-599)DNB1267777966
discipline	Medizin
edition	5. Auflage
format	Book
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02152nam a2200529 c 4500</leader><controlfield tag="001">BV048470141</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20221221 </controlfield><controlfield tag="007">t\|</controlfield><controlfield tag="008">220915s2022 gw a\|\|\| \|\|\|\| 00\|\|\| ger d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">22,N37</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1267777966</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837416312</subfield><subfield code="c">: EUR 44.80 (DE), EUR 46.10 (AT), CHF 74.00 (freier Preis)</subfield><subfield code="9">978-3-8374-1631-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3837416313</subfield><subfield code="9">3-8374-1631-3</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783837416312</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1344383661</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1267777966</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-HB</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-578</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 6200</subfield><subfield code="0">(DE-625)153508:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 6203</subfield><subfield code="0">(DE-625)153508:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WE 555</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="8">1\p</subfield><subfield code="a">610</subfield><subfield code="2">23sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Köhler, Wolfgang</subfield><subfield code="d">1957-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)137076835</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Myasthenia gravis</subfield><subfield code="c">Wolfgang Köhler, Jörn Peter Sieb</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">5. Auflage</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen ; London ; Boston</subfield><subfield code="b">UNI-MED</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">192 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">24.6 cm x 17.6 cm, 496 g</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED Science</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Myasthenia gravis</subfield><subfield code="0">(DE-588)4075144-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Myasthenia gravis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">autoimmunologische Erkrankung</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Therapie</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Myasthenia gravis</subfield><subfield code="0">(DE-588)4075144-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sieb, Jörn Peter</subfield><subfield code="d">1961-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)112255612</subfield><subfield code="4">aut</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">UNI-MED Verlag AG</subfield><subfield code="0">(DE-588)1065561733</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="780" ind1="0" ind2="0"><subfield code="i">Vorangegangen ist</subfield><subfield code="z">9783837413083</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=8fbbc38b8b6241d795d2c98065d12981&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033847952&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">vlb</subfield><subfield code="d">20220910</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#vlb</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033847952</subfield></datafield></record></collection>
id	DE-604.BV048470141
illustrated	Illustrated
indexdate	2024-12-20T19:45:55Z
institution	BVB
institution_GND	(DE-588)1065561733
isbn	9783837416312 3837416313
language	German
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-033847952
oclc_num	1344383661
open_access_boolean
owner	DE-384 DE-578 DE-19 DE-BY-UBM
owner_facet	DE-384 DE-578 DE-19 DE-BY-UBM
physical	192 Seiten Illustrationen 24.6 cm x 17.6 cm, 496 g
publishDate	2022
publishDateSearch	2022
publishDateSort	2022
publisher	UNI-MED
record_format	marc
series2	UNI-MED Science
spellingShingle	Köhler, Wolfgang 1957- Sieb, Jörn Peter 1961- Myasthenia gravis Myasthenia gravis (DE-588)4075144-2 gnd
subject_GND	(DE-588)4075144-2
title	Myasthenia gravis
title_auth	Myasthenia gravis
title_exact_search	Myasthenia gravis
title_full	Myasthenia gravis Wolfgang Köhler, Jörn Peter Sieb
title_fullStr	Myasthenia gravis Wolfgang Köhler, Jörn Peter Sieb
title_full_unstemmed	Myasthenia gravis Wolfgang Köhler, Jörn Peter Sieb
title_short	Myasthenia gravis
title_sort	myasthenia gravis
topic	Myasthenia gravis (DE-588)4075144-2 gnd
topic_facet	Myasthenia gravis
url	http://deposit.dnb.de/cgi-bin/dokserv?id=8fbbc38b8b6241d795d2c98065d12981&prov=M&dok_var=1&dok_ext=htm http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=033847952&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
work_keys_str_mv	AT kohlerwolfgang myastheniagravis AT siebjornpeter myastheniagravis AT unimedverlagag myastheniagravis

Verfügbarkeit

‌

Inhaltsverzeichnis